• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

帕唑帕尼联合治疗方案对一例FGFR3扩增胃腺癌的疗效

Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma.

作者信息

Limaye Sewanti, Patil Darshana, Akolkar Dadasaheb, Srivastava Navin, Patil Revati, Apurwa Sachin, Patil Sanket, John Jinumary, Gosavi Rahul, Nesargikar Prabhu, Kumar Prashant, Datta Vineet, Bose Chirantan, Raazi Zarrine, Srinivasan Ajay, Datar Rajan

机构信息

Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute Mumbai Maharashtra India.

Datar Cancer Genetics Nasik Maharashtra India.

出版信息

Clin Case Rep. 2021 Nov 7;9(11):e04986. doi: 10.1002/ccr3.4986. eCollection 2021 Nov.

DOI:10.1002/ccr3.4986
PMID:34765202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8572349/
Abstract

Angiogenesis inhibitors (AGI) are not presently used for the treatment of gastric cancers. This report demonstrates that angiogenesis inhibitor can be safely and effectively used in combination with cytotoxic anti-cancer agents for treatment of Gastric cancers.

摘要

血管生成抑制剂（AGI）目前尚未用于治疗胃癌。本报告表明，血管生成抑制剂可与细胞毒性抗癌药物联合使用，安全有效地治疗胃癌。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/8572349/c2680a4b0c17/CCR3-9-e04986-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/8572349/c2680a4b0c17/CCR3-9-e04986-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8168/8572349/c2680a4b0c17/CCR3-9-e04986-g002.jpg

相似文献

1
Response to pazopanib-based combination regimen in a case of FGFR3 amplified gastric adenocarcinoma.帕唑帕尼联合治疗方案对一例FGFR3扩增胃腺癌的疗效
Clin Case Rep. 2021 Nov 7;9(11):e04986. doi: 10.1002/ccr3.4986. eCollection 2021 Nov.
2
Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.全外显子组测序揭示 FGFR3-TACC3 靶向治疗耐药的潜在机制及后续药物选择：迈向个体化医学。
BMC Med Genomics. 2020 Sep 21;13(1):138. doi: 10.1186/s12920-020-00794-x.
3
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.米托蒽醌节拍化疗联合帕唑帕尼治疗卵巢癌：在细胞毒性药物与生物治疗之间架起桥梁。
Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.
4
Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.帕唑帕尼，一种新型的多靶点激酶抑制剂，在具有 FGFR2 扩增的胃癌细胞系中显示出强大的体外抗肿瘤活性。
Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23.
5
Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: a case report and literature review.胃腺癌肉瘤伴 FGFR2 扩增经帕唑帕尼长期控制：病例报告及文献复习。
BMC Gastroenterol. 2022 Jul 28;22(1):360. doi: 10.1186/s12876-022-02432-5.
6
Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.胃癌抗血管生成靶向治疗及联合治疗的临床进展
Front Oncol. 2023 Jun 12;13:1148131. doi: 10.3389/fonc.2023.1148131. eCollection 2023.
7
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.帕唑帕尼在肿瘤血管生成和癌症治疗中的作用：综述。
Biomed Pharmacother. 2017 Dec;96:768-781. doi: 10.1016/j.biopha.2017.10.058. Epub 2017 Nov 6.
8
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.帕唑帕尼或拉帕替尼单药治疗与帕唑帕尼联合拉帕替尼联合治疗在晚期和复发性宫颈癌患者中的 II 期、开放标签研究。
J Clin Oncol. 2010 Aug 1;28(22):3562-9. doi: 10.1200/JCO.2009.26.9571. Epub 2010 Jul 6.
9
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.帕唑帕尼联合氟尿嘧啶和奥沙利铂一线治疗晚期胃癌：一项随机 II 期研究——PaFLO 试验。一项由德国肿瘤内科学会（AIO）STO 0510 协作组开展的研究。
Int J Cancer. 2022 Mar 15;150(6):1007-1017. doi: 10.1002/ijc.33864. Epub 2021 Nov 15.
10
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.帕唑帕尼联合 CapeOX（卡培他滨和奥沙利铂）用于既往未接受治疗的晚期胃癌患者的前瞻性 II 期试验。
Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175.

引用本文的文献

1
Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model.泊那替尼使高危 VQ 模型中的骨髓瘤细胞对 MEK 抑制敏感。
Sci Rep. 2022 Jun 23;12(1):10616. doi: 10.1038/s41598-022-14114-z.
2
FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?胃癌中的FGFR通路抑制：旧靶点的黄金时代？
Life (Basel). 2022 Jan 7;12(1):81. doi: 10.3390/life12010081.

本文引用的文献

1
Current treatment and recent progress in gastric cancer.胃癌的当前治疗方法和最新进展。
CA Cancer J Clin. 2021 May;71(3):264-279. doi: 10.3322/caac.21657. Epub 2021 Feb 16.
2
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.FGFR抑制剂培米替尼在转移性食管胃交界部/胃癌曲妥珠单抗耐药患者中的II期试验：FiGhTeR试验
Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020.
3
Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial.
用于指导晚期广泛难治性癌症治疗的肿瘤百科分析：RESILIENT试验结果
Oncotarget. 2019 Sep 24;10(54):5605-5621. doi: 10.18632/oncotarget.27188.
4
Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis.靶向胃癌发生中的致癌性 FGF-FGFR 轴。
Cells. 2019 Jun 25;8(6):637. doi: 10.3390/cells8060637.
5
Pazopanib in advanced soft tissue sarcomas.帕唑帕尼治疗晚期软组织肉瘤。
Signal Transduct Target Ther. 2019 May 17;4:16. doi: 10.1038/s41392-019-0049-6. eCollection 2019.
6
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.拉罗替尼治疗成人实体瘤患者的多中心、开放标签、I 期剂量递增研究。
Ann Oncol. 2019 Feb 1;30(2):325-331. doi: 10.1093/annonc/mdy539.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Pazopanib Sensitivity in a Patient With Breast Cancer and Amplification.乳腺癌伴扩增患者对帕唑帕尼的敏感性。
J Natl Compr Canc Netw. 2017 Dec;15(12):1456-1459. doi: 10.6004/jnccn.2017.7030.
9
An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.FGFR3 自分泌环路维持胃癌患者对曲妥珠单抗的获得性耐药。
Clin Cancer Res. 2016 Dec 15;22(24):6164-6175. doi: 10.1158/1078-0432.CCR-16-0178. Epub 2016 Jun 7.
10
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.帕唑帕尼联合 CapeOX（卡培他滨和奥沙利铂）用于既往未接受治疗的晚期胃癌患者的前瞻性 II 期试验。
Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175.